Want to join the conversation?
$BSX said that it is increasing 2016 adjusted operating margin guidance to 24.0-24.5%. With the exception of the 3% decline in the Cardiac Rhythm Management sales, all of the other businesses delivered strong organic growth led by Endo at 11%, Urology and Public Health at 12%, Interventional Cardiology at 13% and Peripheral Interventions at 14%.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.